Table 3.
Variables | Univariate |
Multivariate |
||
---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | |
Gender | 0.872 | |||
Female | 0.96 (0.588–1.57) | |||
Male | 1 | |||
Age | 0.033 | 0.022 | ||
≦48 | 1.709 (1.044–2.799) | 1.837 (1.093–3.086) | ||
≧49 | 1 | 1 | ||
MGFA classification | 0.723 | |||
I + IIA | 0.889 (0.465–1.70) | |||
IIB + III | 1 | |||
WHO histologic type | 0.227 | |||
A + AB | 1.428 (0.801–2.543) | |||
B1 + B2 + B3 | 1 | |||
Masaoka–Koga stage | 0.901 | |||
I | 1.055 (0.455–2.444) | |||
II | 1 | |||
Steroids preoperatively | 0.279 | |||
Yes | 0.736 (0.423–1.281) | |||
No | 1 | |||
Immunosuppressive drugs preoperatively | 0.326 | |||
Yes | 0.702 (0.347–1.422) | |||
No | 1 | |||
Perioperative immunoglobin | 0.339 | |||
Yes | 0.773 (0.457–1.31) | |||
No | 1 | |||
Surgical approach | 0.033 | 0.016 | ||
Subxiphoid | 1.701 (1.044–2.773) | 1.892 (1.127–3.177) | ||
Trans-sternal | 1 | 1 |
MGFA, Myasthenia Gravis Foundation of America; HR, hazard ratio; CI, confidence interval.